TR200806646A2 - Pharmaceutical combinations including entacapone, levodopa and carbidoba - Google Patents

Pharmaceutical combinations including entacapone, levodopa and carbidoba

Info

Publication number
TR200806646A2
TR200806646A2 TR2008/06646A TR200806646A TR200806646A2 TR 200806646 A2 TR200806646 A2 TR 200806646A2 TR 2008/06646 A TR2008/06646 A TR 2008/06646A TR 200806646 A TR200806646 A TR 200806646A TR 200806646 A2 TR200806646 A2 TR 200806646A2
Authority
TR
Turkey
Prior art keywords
levodopa
entacapone
pharmaceutical combinations
carbidoba
combinations including
Prior art date
Application number
TR2008/06646A
Other languages
Turkish (tr)
Inventor
Ebrahi̇mi̇ Şi̇ri̇n
Badem Gülhan
Ağcayazi Mehmet
Original Assignee
Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. filed Critical Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş.
Priority to TR2008/06646A priority Critical patent/TR200806646A2/en
Publication of TR200806646A2 publication Critical patent/TR200806646A2/en
Priority to PCT/TR2009/000112 priority patent/WO2010027340A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş entakapon, levodopa ve karbodiba içeren farmasötik kombinasyonlarla ilgili olup, özelliği; entakapon, levodopa ve karbidopa veya bu moleküllerin kabul edilebilir tuz, sulu formları veya fizikokimyasal açıdan her türlü polimorflarını içeren, farmasötik olarak stabil kompozisyonlarının Parkinson Hastalığı tedavisine yönelik olarak hazırlanmasına dair kompozisyonlar ve bu kompozisyonların hazırlanışını kapsamasıdır.The invention relates to pharmaceutical combinations containing entacapone, levodopa and carbodiba. Compositions for the preparation of pharmaceutically stable compositions for the treatment of Parkinson's Disease, comprising entacapone, levodopa and carbidopa, or any acceptable salt, aqueous forms or any physicochemically polymorphs of these molecules, and the preparation of these compositions.

TR2008/06646A 2008-09-03 2008-09-03 Pharmaceutical combinations including entacapone, levodopa and carbidoba TR200806646A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2008/06646A TR200806646A2 (en) 2008-09-03 2008-09-03 Pharmaceutical combinations including entacapone, levodopa and carbidoba
PCT/TR2009/000112 WO2010027340A1 (en) 2008-09-03 2009-09-03 Pharmaceutical compositions composing entakapon, levodopa and karbidoba

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2008/06646A TR200806646A2 (en) 2008-09-03 2008-09-03 Pharmaceutical combinations including entacapone, levodopa and carbidoba

Publications (1)

Publication Number Publication Date
TR200806646A2 true TR200806646A2 (en) 2009-06-22

Family

ID=41314610

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/06646A TR200806646A2 (en) 2008-09-03 2008-09-03 Pharmaceutical combinations including entacapone, levodopa and carbidoba

Country Status (2)

Country Link
TR (1) TR200806646A2 (en)
WO (1) WO2010027340A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026419B1 (en) 2010-03-04 2017-04-28 Орион Корпорейшн Use of levodopa, carbidopa and entacapone for treating parkinson's disease
TR201204839A2 (en) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Tablet formulation containing levodopa carbidopa entacapone for prolonged release.
BR112015022390A8 (en) * 2013-03-13 2019-11-26 Neuroderm Ltd use of carbidopa, levodopa and a comt inhibitor for the preparation of a composition for treating parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (en) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Pharmaceutical composition
JP2008519811A (en) * 2004-11-10 2008-06-12 オリオン コーポレーション Treatment of restless leg syndrome
US20060222703A1 (en) * 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
US20080187590A1 (en) * 2005-06-08 2008-08-07 Kari Vahervuo Oral Dosage Form
EP2104424A4 (en) * 2006-10-30 2011-06-15 Wockhardt Research Center Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
ATE510537T1 (en) * 2008-02-06 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE, LEVODOPA AND CARBIDOPA WITH IMPROVED BIOAVAILABILITY

Also Published As

Publication number Publication date
WO2010027340A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
CY1119575T1 (en) Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
EA200971107A1 (en) CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease
CY1118374T1 (en) TRAMADOL CO-CRYSTALS AND NSAIDs
NO20074823L (en) Rasagilin formulations with improved content uniformity
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EA200970287A1 (en) METHODS, COMPOUNDS, COMPOSITIONS AND MEDIA SUITABLE FOR DELIVERY OF 3-AMINO-1-PROPANSULPHONE ACID
MX336774B (en) Quinoline amide m1 receptor positive allosteric modulators.
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EA201370208A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
BRPI0508051A (en) heteroarylaminopyrazole derivatives usable for the treatment of diabetes
BRPI0516483A (en) preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
EA201270480A1 (en) NEW CONNECTIONS
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
EA200900044A1 (en) SUBSTITUTED DERIVATIVES 1,3-DIPHENYL PROPER, RECEIVING AND THEIR USE
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
UA98961C2 (en) Pyrazinone derivatives and their use in the treatment of lung diseases
EA201071045A1 (en) COMPOUNDS OF OXADIAZOANTHRACENE FOR THE TREATMENT OF DIABETES
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
ATE530544T1 (en) BENZYL-SUBSTITUTED POSITIVE ALLOSTERIC QUINOLONE M1 RECEPTOR MODULATORS
BRPI0820668A2 (en) 5-HALOGEN SUBSTITUTED OXINDOL DERIVATIVES AND THEIR USE TO TREAT VASOPRESSIN DEPENDENT DISEASES